Cleared Traditional

SPACE-OR RETRACTOR (K993544) - FDA 510(k) Clearance

Class I Gastroenterology & Urology device.

K993544 · Advanced Surgical Concepts (Asc) · Gastroenterology & Urology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1999
Decision
64d
Days
Class 1
Risk

K993544 is an FDA 510(k) clearance for the SPACE-OR RETRACTOR. Classified as Retractor, Self-retaining (product code FFO), Class I - General Controls.

Submitted by Advanced Surgical Concepts (Asc) (North Attleboro, US). The FDA issued a Cleared decision on December 22, 1999 after a review of 64 days - a notably fast clearance cycle.

This device falls under the Gastroenterology & Urology FDA review panel, regulated under 21 CFR 876.4730 - the FDA gastroenterology and urology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Advanced Surgical Concepts (Asc) devices

Submission Details

510(k) Number K993544 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 19, 1999
Decision Date December 22, 1999
Days to Decision 64 days
Submission Type Traditional
Review Panel Gastroenterology & Urology (GU)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
66d faster than avg
Panel avg: 130d · This submission: 64d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code FFO Retractor, Self-retaining
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 876.4730
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.